Immunovant
$39.19
30
-$1.08-2.68% Friday 21:00
Statistics
Day High
40.26
Day Low
38.57
52W High
44.19
52W Low
14.05
Volume
972,778
Avg. Volume
1,416,412
Mkt Cap
5.67B
P/E Ratio
0
Dividend Yield
-
Dividend
-
Upcoming
Earnings
1FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.57
-0.5
-0.42
-0.35
Expected EPS
-0.44
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow IMVT. It's not an investment recommendation.
Analyst Ratings
45.7$Average Price Target
The highest estimate is $57.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Finance
Financial Conglomerates
Health Technology
Biotechnology
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Show more...
CEO
Employees
68
Country
US
ISIN
US45258J1025